GPS Wealth Strategies Group LLC Grows Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

GPS Wealth Strategies Group LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.7% in the second quarter, HoldingsChannel reports. The firm owned 275 shares of the medical research company’s stock after buying an additional 31 shares during the period. GPS Wealth Strategies Group LLC’s holdings in Thermo Fisher Scientific were worth $152,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Summa Corp. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $418,000. Private Wealth Management Group LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $110,000. Brookstone Capital Management raised its position in shares of Thermo Fisher Scientific by 252.4% in the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after acquiring an additional 3,142 shares during the period. Y.D. More Investments Ltd lifted its position in shares of Thermo Fisher Scientific by 33.9% during the 4th quarter. Y.D. More Investments Ltd now owns 391 shares of the medical research company’s stock valued at $207,000 after buying an additional 99 shares in the last quarter. Finally, Private Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 1.0% in the 4th quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock worth $45,187,000 after buying an additional 815 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.0 %

Shares of NYSE TMO traded down $0.09 during trading on Thursday, reaching $602.01. The stock had a trading volume of 304,477 shares, compared to its average volume of 1,544,905. The business’s 50-day moving average price is $569.93 and its 200-day moving average price is $571.23. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $622.30. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The company has a market cap of $229.80 billion, a P/E ratio of 38.66, a PEG ratio of 2.77 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.15 earnings per share. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.71 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,084 shares of company stock worth $19,767,092. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on TMO. Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Raymond James upped their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Barclays lowered their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Finally, HSBC raised their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $618.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.